Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats

Journal of the American Society of Nephrology

Volumn 16, Issue 3, 2005, Pages 703-711

  Nagai, Yukiko ^a   Yao, Li ^a   Kobori, Hiroyuki ^b   Miyata, Kayoko ^a   Ozawa, Yuri ^c   Miyatake, Akira ^a   Yukimura, Tokihito ^b   Shokoji, Takatomi ^a   Kimura, Shoji ^a   Kiyomoto, Hideyasu ^a   Kohno, Masakazu ^a   Abe, Youichi ^a   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; HYDRALAZINE; OLMESARTAN; TEMOCAPRIL; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAZOLE DERIVATIVE; IMMEDIATE EARLY PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; SIGNAL PEPTIDE; TETRAZOLE DERIVATIVE; THIAZEPINE DERIVATIVE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; KIDNEY INJURY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEINURIA; RAT; ANIMAL; BLOOD PRESSURE; BODY WEIGHT; DIABETIC NEPHROPATHY; DRUG COMBINATION; GENETICS; GLUCOSE BLOOD LEVEL; IMPAIRED GLUCOSE TOLERANCE; METABOLISM; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; COLLAGEN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; HYDRALAZINE; IMIDAZOLES; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NADPH OXIDASE; PREDIABETIC STATE; RATS; RATS, INBRED OLETF; RECEPTORS, ANGIOTENSIN; RENIN; TETRAZOLES; THIAZEPINES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRANSFORMING GROWTH FACTOR BETA;

EID: 20544471721     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004080649     Document Type: Article

References (36)

1. Makino H, Nakamura Y, Wada J: Remission and regression of diabetic nephropathy. Hypertens Res 26: 515-519, 2003
2. Rincon-Choles H, Kasinath BS, Gorin Y, Abboud HE: Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl 82: S8-S11, 2002
3. Berl T: Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: The case for AT1 receptor antagonist. J Am Soc Nephrol 15[Suppl 1]: S71-S76, 2004
4. Deferrari G, Ravera M, Deferrari L, Vettoretti S, Ratto E, Parodi D: Renal and cardiovascular protection in type 2 diabetes mellitus: Angiotensin II receptor blockers. J Am Soc Nephrol 13[Suppl 3]: S224-S229, 2002
5. Carey RM, Siragy HM: The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 14: 274-281, 2003
6. Burns KD: Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 36: 449-467, 2000
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
8. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106: 672-678, 2002
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
10. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
11. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
12. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: 577-581, 1993
13. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349: 1787-1792, 1997
14. Wu JN, Berecek KH: Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 22: 139-146, 1993
15. Giudicelli JF, Freslon JL, Glasson S, Richer C: Captopril and hypertension development in the SHR. Clin Exp Hypertens 2: 1083-1096, 1980
16. Unger T, Rettig R: Development of genetic hypertension. Is there a "critical phase"? Hypertension 16: 615-616, 1990
17. Nyborg NC, Mulvany MJ: Lack of effect of anti-hypertensive treatment with felodipine on cardiovascular structure of young spontaneously hypertensive rats. Cardiovasc Res 19: 528-536, 1985
18. Wang H, Katovich MJ, Gelband CH, Reaves PY, Phillips MI, Raizada MK: Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA. Circ Res 85: 614-622, 1999
19. Nakaya H, Sasamura H, Hayashi M, Saruta T: Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 12: 659-666, 2001
20. Nakaya H, Sasamura H, Mifune M, Shimizu-Hirota R, Kuroda M, Hayashi M, Saruta T: Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron 91: 710-718, 2002
21. Uehara Y, Hirawa N, Numabe A, Kawabata Y, Nagoshi H, Negoro H, Fujiwara S, Gomi T, Ikeda T, Goto A, Omata M: Angiotensin-converting enzyme inhibition delays onset of glucosuria with regression of renal injuries in genetic rat model of non-insulin-dependent diabetes mellitus. J Cardiovasc Pharmacol Ther 3: 327-336, 1998
22. Koga K, Yamagishi S, Takeuchi M, Inagaki Y, Amano S, Okamoto T, Saga T, Makita Z, Yoshizuka M: CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Mol Med 8: 591-599, 2002
23. Okada M, Takemura T, Yanagida H, Yoshioka K: Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats. Kidney Int 61: 113-124, 2002
24. Yao L, Kobori H, Rahman M, Seth DM, Shokoji T, Fan Y, Zhang GX, Kimura S, Abe Y, Nishiyama A: Olmesartan improves endothelin-induced hypertension and oxidative stress in rats. Hypertens Res 27: 493-500, 2004
25. Nishiyama A, Yoshizumi M, Rahman M, Kobori H, Seth DM, Miyatake A, Zhang GX, Yao L, Hitomi H, Shokoji T, Kiyomoto H, Kimura S, Tamaki T, Kohno M, Abe Y: Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats. Kidney Int 65: 972-981, 2004
26. Prieto-Carrasquero MC, Harrison-Bernard LM, Kobori H, Ozawa Y, Hering-Smith KS, Hamm LL, Navar LG: Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension 44: 223-229, 2004
27. Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, Rahman M, Hitomi H, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y: Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 42: 754-760, 2003
28. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y: Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43: 841-848, 2004
29. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACEI and ARB. Kidney Int 61: 186-194, 2002
30. Griendling KK, Ushio-Fukai M: Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 91: 21-27, 2000
31. Wilcox CS: Reactive oxygen species: Roles in blood pressure and kidney function. Curr Hypertens Rep 4: 160-166, 2002
32. Ha H, Lee HB: Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol 14[Suppl 3]: S246-S249, 2003
33. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H: Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 14[Suppl 3]: S241-S245, 2003
34. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A: CTGF expression in mesangial cells: Involvement of SMADs, MAP kinase, and PKC. Kidney Int 62: 1149-1159, 2002
35. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11: 25-38, 2000
36. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, Sugawara A, Nakao K: Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 15: 1430-1440, 2004